Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Dextromethorphan/quinidine (Nuedexta) for pseudobulbar affect.

[No authors listed]

Med Lett Drugs Ther. 2011 Jun 13;53(1366):46-7. No abstract available. Erratum in: Med Lett Drugs Ther. 2011 Jul 11;53(1368):56.

PMID:
21659969
2.

Dextromethorphan/quinidine for the treatment of pseudobulbar affect.

Patatanian E, Casselman J.

Consult Pharm. 2014 Apr;29(4):264-9. doi: 10.4140/TCP.n.2014.264. Review.

PMID:
24704895
3.

Dextromethorphan/quinidine sulfate for pseudobulbar affect.

Rosen H.

Drugs Today (Barc). 2008 Sep;44(9):661-8. doi: 10.1358/dot.2008.44.9.1258664. Review.

4.

A naturalistic on-off-on trial of dextromethorphan/quinidine for agitation associated with cerebellar injury.

Daly JP, Caplan JP.

Psychosomatics. 2012 Sep-Oct;53(5):470-3. doi: 10.1016/j.psym.2011.11.001. Epub 2012 Mar 27. No abstract available.

PMID:
22458990
5.

Treatment of pseudobulbar affect in ALS: October 26 highlight and commentary.

Hingorani VN, Kittrelle JP.

Neurology. 2005 May 24;64(10):1821; author reply 1821. No abstract available.

PMID:
15911831
6.

NueDexta: A Treatment for Pseudobulbar Affect.

Roman MW.

Issues Ment Health Nurs. 2015;36(12):1019-21. doi: 10.3109/01612840.2015.1091869. No abstract available.

PMID:
26735510
7.

Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial.

Brooks BR, Thisted RA, Appel SH, Bradley WG, Olney RK, Berg JE, Pope LE, Smith RA; AVP-923 ALS Study Group.

Neurology. 2004 Oct 26;63(8):1364-70.

PMID:
15505150
8.

Treatment of pseudobulbar affect in ALS.

Smith RA, Brooks BR.

Lancet Neurol. 2005 May;4(5):270. No abstract available.

PMID:
15847840
9.

An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions.

Pattee GL, Wymer JP, Lomen-Hoerth C, Appel SH, Formella AE, Pope LE.

Curr Med Res Opin. 2014 Nov;30(11):2255-65. doi: 10.1185/03007995.2014.940040. Epub 2014 Jul 28.

10.

Dextromethorphan/quinidine: in pseudobulbar affect.

Garnock-Jones KP.

CNS Drugs. 2011 May;25(5):435-45. doi: 10.2165/11207260-000000000-00000. Review.

PMID:
21476614
11.

PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury.

Hammond FM, Alexander DN, Cutler AJ, D'Amico S, Doody RS, Sauve W, Zorowitz RD, Davis CS, Shin P, Ledon F, Yonan C, Formella AE, Siffert J.

BMC Neurol. 2016 Jun 9;16:89. doi: 10.1186/s12883-016-0609-0. Erratum in: BMC Neurol. 2016;16(1):160.

12.

Therapeutic use of dextromethorphan: key learnings from treatment of pseudobulbar affect.

Miller A, Panitch H.

J Neurol Sci. 2007 Aug 15;259(1-2):67-73. Epub 2007 Apr 16. Review.

PMID:
17433820
13.

Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis.

Panitch HS, Thisted RA, Smith RA, Wynn DR, Wymer JP, Achiron A, Vollmer TL, Mandler RN, Dietrich DW, Fletcher M, Pope LE, Berg JE, Miller A; Psuedobulbar Affect in Multiple Sclerosis Study Group.

Ann Neurol. 2006 May;59(5):780-7.

PMID:
16634036
14.

Dextromethorphan/quinidine: a review of its use in adults with pseudobulbar affect.

Yang LP, Deeks ED.

Drugs. 2015 Jan;75(1):83-90. doi: 10.1007/s40265-014-0328-z. Review.

PMID:
25420446
15.

Pseudobulbar affect: the spectrum of clinical presentations, etiologies and treatments.

Miller A, Pratt H, Schiffer RB.

Expert Rev Neurother. 2011 Jul;11(7):1077-88. doi: 10.1586/ern.11.68. Epub 2011 May 3. Review.

PMID:
21539437
16.

Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect.

Pioro EP, Brooks BR, Cummings J, Schiffer R, Thisted RA, Wynn D, Hepner A, Kaye R; Safety, Tolerability, and Efficacy Results Trial of AVP-923 in PBA Investigators.

Ann Neurol. 2010 Nov;68(5):693-702. doi: 10.1002/ana.22093.

PMID:
20839238
17.

Therapeutic options for emotional lability: current and emerging treatments.

Weintraub D.

Am J Geriatr Pharmacother. 2005;3 Suppl A:12-5; quiz 16-7. No abstract available.

PMID:
16305945
18.
20.

Effects of dextromethorphan/quinidine on auditory event-related potentials in multiple sclerosis patients with pseudobulbar affect.

Haiman G, Pratt H, Miller A.

J Clin Psychopharmacol. 2009 Oct;29(5):444-52. doi: 10.1097/JCP.0b013e3181b5ae5c.

PMID:
19745644

Supplemental Content

Support Center